PMID: 2120649Nov 1, 1990Paper

Human immunoglobulin therapy for preeclampsia associated with lupus anticoagulant and anticardiolipin antibody

Obstetrics and Gynecology
V L KatzR P Heine

Abstract

A patient with lupus anticoagulant and anticardiolipin antibody developed preeclampsia at 24 weeks' gestation. Therapy with human immunoglobulin (Ig) resulted in stabilization of preeclampsia and suppression of the lupus anticoagulant. Anticardiolipin antibody titers were partially suppressed. Preeclampsia worsened at 32 weeks' gestation, and a healthy infant was delivered. For patients with preeclampsia secondary to lupus anticoagulant before the fetus is viable, human Ig is a potential therapeutic option.

Citations

Aug 1, 1995·European Journal of Obstetrics, Gynecology, and Reproductive Biology·D Vinatier, J C Monnier
Jun 1, 1994·The Journal of Steroid Biochemistry and Molecular Biology·E GiacomucciC Flamigni
Aug 1, 1993·The Journal of Dermatologic Surgery and Oncology·F A Kerdel
Feb 1, 1997·Rheumatic Diseases Clinics of North America·S Welsch, D W Branch
Jan 24, 2007·American Journal of Obstetrics and Gynecology·Norbert Gleicher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.